Elsevier Inc.

SHERPA: Unknown

People

  1. Ladanyi
    Ladanyi
  2. Riely
    Riely
  3. Schoenfeld
    Schoenfeld
  4. Drilon
    Drilon
  5. Kris
    Kris
  6. Offin
    Offin
  7. Rekhtman
    Rekhtman
  8. Yu
    Yu
  9. De Stanchina
    De Stanchina
  10. Arcila
    Arcila

Groups

  1. GSK Faculty (26)
  2. Human Oncology and Pathogenesis Program (26)
  3. Sloan Kettering Institute Postdocs (26)
  4. Tow Center for Developmental Oncology (TCDO) (26)
  5. Department of Medicine (20)
  6. Solid Tumor Oncology Division (20)
  7. Thoracic Oncology (20)
  8. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (10)
  9. Hematologic Malignancies, Division of (10)
  10. Biostatistics Service (5)
Search Within
  1. "Marc Ladanyi"
  2. "Sloan Kettering Institute Postdocs"
Formats
  1. Meeting Abstract (14)
  2. Journal Article (12)
Groups
  1. GSK Faculty (26)
  2. Human Oncology and Pathogenesis Program (26)
  3. Sloan Kettering Institute Postdocs (26)
  4. Tow Center for Developmental Oncology (TCDO) (26)
  5. Department of Medicine (20)
  6. Solid Tumor Oncology Division (20)

More Groups

People
  1. Marc Ladanyi (26)
  2. Romel Somwar (16)
  3. Gregory Riely (11)
  4. Adam Schoenfeld (10)
  5. Alexander Drilon (9)
  6. Charles Rudin (9)

More People

Years
  1. 2024 (2)
  2. 2023 (6)
  3. 2022 (2)
  4. 2021 (2)
  5. 2020 (3)
  6. 2019 (8)

More Years

Publications
  1. Journal of Thoracic Oncology (23)
  2. European Journal of Cancer (2)
  3. Human Pathology (1)

Results (26)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Microsatellite instability and mismatch repair deficiency define a distinct subset of lung cancers characterized by smoking exposure, high tumor mutational burden, and recurrent somatic MLH1 inactivation
    Journal Article

    Yang, S. R.; Gedvilaite, E.; Ptashkin, R.; Chang, J.; Ziegler, J.; Mata, D. A.; Villafania, L. B.; Nafa, K.; Hechtman, J. F.; Benayed, R.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • HER4 and EGFR activate cell signaling in NRG1 fusion-driven cancers: Implications for HER2-HER3-specific versus pan-HER targeting strategies
    Journal Article

    Udagawa, H.; Nilsson, M. B.; Robichaux, J. P.; He, J.; Poteete, A.; Jiang, H.; Heeke, S.; Elamin, Y. Y.; Shibata, Y.; Matsumoto, S.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of patients with EGFR-mutant lung cancer with acquired BRAF alterations
    Meeting Abstract

    Sui, J.; Yang, S. R.; Bowman, A. S.; Vankayala, P.; Falcon, C.; Somwar, R.; Drilon, A. E.; Riely, G. J.; Kris, M. G.; Ladanyi, M.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Microsatellite instability defines a subset of lung cancers with smoking exposure, high tumor mutational burden and MLH1 inactivation
    Meeting Abstract

    Yang, S. R.; Gedvilaite, E.; Ptashkin, R.; Chang, J.; Ziegler, J.; Mata, D.; Villafania, L. B.; Nafa, K.; Hechtman, J. F.; Benhamida, J.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Impact of aneuploidy and chromosome 9p loss on tumor immune microenvironment and immune checkpoint inhibitor efficacy in NSCLC
    Journal Article

    Alessi, J. V.; Wang, X.; Elkrief, A.; Ricciuti, B.; Li, Y. Y.; Gupta, H.; Spurr, L. F.; Rizvi, H.; Luo, J.; Pecci, F.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Combination therapy with MDM2 and MEK inhibitors is effective in patient-derived models of lung adenocarcinoma with concurrent oncogenic drivers and MDM2 amplification
    Journal Article

    Elkrief, A.; Odintsov, I.; Markov, V.; Caeser, R.; Sobczuk, P.; Tischfield, S. E.; Bhanot, U.; Vanderbilt, C. M.; Cheng, E. H.; Drilon, A.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced NSCLC
    Journal Article

    Alessi, J. V.; Elkrief, A.; Ricciuti, B.; Wang, X.; Cortellini, A.; Vaz, V. R.; Lamberti, G.; Frias, R. L.; Venkatraman, D.; Fulgenzi, C. A. M.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers
    Journal Article

    Choudhury, N. J.; Marra, A.; Sui, J. S. Y.; Flynn, J.; Yang, S. R.; Falcon, C. J.; Selenica, P.; Schoenfeld, A. J.; Rekhtman, N.; Gomez, D.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Vepafestinib is effective in preclinical models of sarcomas with RET fusion including a brain metastasis model
    Meeting Abstract

    Odintsov, I.; Liu, A.; Khodos, I.; Chang, Q.; Giuliano, C.; Mattar, M.; Vojnic, M.; Bonifacio, A.; De Stanchina, E.; Lovati, E.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • TA0953/HM06, a novel RET-specific inhibitor effective in extracranial and CNS disease models of NSCLC with RETfusions
    Meeting Abstract

    Odintsov, I.; Lui, A. J. W.; Delasos, L.; Khodos, I.; Chang, Q.; Mattar, M. S.; Vojnic, M.; Lu, Y. C.; Kunte, S.; Bonifacio, A.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save